Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease
The Lancet Gastroenterology & Hepatology in conversation with - Een podcast door The Lancet Group
Categorieën:
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease. Read the full article: Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langa...
